发明名称 Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
摘要 The invention relates to azacyclyl-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted aryldihydroisoquinolinone of the invention or its derivative, and the use of the azacyclyl-substituted aryldihydroisoquinolinones of the invention and their derivatives as MCH antagonists.
申请公布号 US8822495(B2) 申请公布日期 2014.09.02
申请号 US200812191662 申请日期 2008.08.14
申请人 Sanofi 发明人 Schwink Lothar;Stengelin Siegfried;Gossel Matthias;Hessler Gerhard;Haack Torsten;Lennig Petra
分类号 A61K31/551;A61K31/541;A61K31/5377;A61K31/496;A61K31/4725;C07D405/14;C07D401/14;C07D401/10;C07D487/04;C07D487/10;C07D417/14;C07D513/04;C07D413/14;C07D407/14;C07D413/04 主分类号 A61K31/551
代理机构 Scully, Scott, Murphy & Presser, P.C. 代理人 Scully, Scott, Murphy & Presser, P.C.
主权项 1. A compound of formula (I)wherein: R1, R1′, R1″ and R1′″ are independently of one another H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R3)(R4), SO2—CH3, COOH, COO—(C1-C6)-alkyl, CON(R5)(R6), N(R7)CO(R8), N(R9)SO2(R10), CO(R11), or (C(R12)(R13))x—O(R14); R3, R4, R5, R6, R7 and R9 are independently of one another H or (C1-C8)-alkyl, or R3 and R4, or R5 and R6 independently of one another taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally contains one additional heteroatom selected from the group consisting of NH, N—(C1-C6)-alkyl, oxygen and sulfur; R8, R10 and R11 are independently of one another H, (C1-C8)-alkyl, or aryl; R12 and R13 are independently of one another H, or (C1-C8)-alkyl; R14 is H, (C1-C6)-alkyl, or aryl; x is 0, 1, 2, 3, 4, 5, or 6; R2 is H; Y is C(R27)(R27′)C(R28)(R28′) or C(R29)=C(R29′); R27, R27′, R28, R28′, R29 and R29′ are H; X is S, O, or C(R30)=C(R30′); R30 and R30′ are H; A is a bond or a linker having 1 to 8 members, where the members are selected from the group consisting of O, S, SO2, N(R31), CO, C(R32)(R33), C(R34)=C(R34′), cyclopropylene, and C≡C, resulting in a chemically reasonable radical; R31, R34 and R34′ are independently of one another H or (C1-C8)-alkyl; R32 and R33 are independently of one another H, (C1-C6)-alkyl, OH, or O—(C1-C6)-alkyl; B is N(R35)(R36), hydroxy-(C1-C4)-alkyl, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic nonaromatic ring which contains 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, and the ring system is optionally substituted one or more times by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, oxo, CO(R37), CON(R38)(R39), hydroxy, COO(R40), N(R41)CO(C1-C6)-alkyl, N(R42)(R43), SO2CH3, SCF3 or S—(C1-C6)-alkyl; R35, R36, R37, R38, R39, R40, R41, R42 and R43 are independently of one another H, or (C1-C8)-alkyl; or R38 and R39, or R42 and R43 independently of one another taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally contains one additional heteroatom selected from the group consisting of NH, N—(C1-C6)-alkyl, oxygen and sulfur; Q is mono-, bi-, tri- or spirocyclic saturated or partly unsaturated ring structure having one nitrogen atom and 0-3 additional heteroatoms selected from the group consisting of N, O and S, where the ring of the structure may be spiro-linked, fused or bridged, and where the ring system is optionally substituted one or more times by substituents selected from the group consisting of F, OH, CF3, CN, OCF3, oxo, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R44), (C(R45)(R46))o-R47, and CO(C(R45)(R46))p-R48, where Q contains in total at least two N atoms; or Q is selected from the group consisting of: each of which is optionally substituted one or more times by F, OH, oxo, (C1-C6)-alkyl, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, or hydroxy-(C1-C4)-alkyl; R44 is H or (C1-C8)-alkyl; R45 and R46 are independently of one another H, (C1-C8)-alkyl, OH, (C3-C8)-cycloalkyl, or (C1-C4)-alkoxy-(C1-C4)-alkyl; o and p are independently of one another 0, 1, 2, 3, 4, 5 or 6; R47 and R48 are independently of one another OH, F, O—(C1-C8)-alkyl, CON(R49)(R50), N(R51)CO(R52), N(R53)(R54), CO2(R55), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group of N, O and S, which may be substituted by one or more of the following substituents: F, Cl, Br, CF3, (C1-C8)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO(R56), oxo, or OH; R49, R50, R51, R52, R55 and R56 are independently of one another H or (C1-C8)-alkyl, or R49 and R50 taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally contains one additional heteroatom selected from the group consisting of NH, N—(C1-C6)-alkyl, oxygen and sulfur; R53 and R54 are independently of one another H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, CO(R57), (C(R58)(R59))q-R60, CO(C(R61)(R62))r-R63, or CO—O(C1-C8)-alkyl, or R53 and R54 taken together with the nitrogen atom to which they are bonded form a 4 to 10-membered mono-, bi- or spirocyclic ring which optionally contains 1 to 3 additional heteroatoms selected from the group consisting of N, O and S, and is optionally substituted one or more times by F, Cl, Br, CF3, O—(C1-C8)-alkyl, (C1-C6)-alkyl, CO(R64), oxo, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, CON(R65)(R66), N(R67)CO(R68), N(R69)(R70), CO2(R71), or SO2(C1-C6)-alkyl; R58 and R59 are independently of one another H, (C1-C6)-alkyl, or OH; R57, R61, R62, R64, R65, R66, R67, R68, R69, R70 and R71 are independently of one another H or (C1-C6)-alkyl, or R69 and R70 taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally contains one additional heteroatom selected from the group consisting of NH, N—(C1-C6)-alkyl, oxygen and sulfur; q and r are independently of one another 0, 1, 2, 3, 4, 5 or 6; R60 and R63 are independently of one another OH, F, O—(C1-C6)-alkyl, CN, COO(R78), N(R74)CO(C1-C6)-alkyl, N(R76)(R77), CON(R72)(R73), SO2(C1-C6)-alkyl, or 3-12 membered mono-, bi- or spirocyclic ring which optionally contains one or more heteroatoms selected from the group consisting of N, O and S, and the 3-12 membered ring is optionally substituted by F, Cl, Br, OH, CF3, NO2, CN, OCF3, oxo, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, N(R76)(R77), COO(R78), SO2(C1-C6)-alkyl or COOH; and R72, R73, R74, R76, R77 and R78 are independently of one another H or (C1-C8)-alkyl, or R72 and R73, or R76 and R77 independently of one another taken together with the nitrogen atom to which they are bonded form a 5-6 membered ring which optionally contains one additional heteroatom selected from the group consisting of NH, N—(C1-C6)-alkyl, oxygen and sulfur; or a hydrate, solvate, or pharmaceutically acceptable salt thereof.
地址 Paris FR